Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Implementation of the German Mammography Screening Program (German MSP) and First Results for Initial Examinations, 2005-2009.

Malek D, Kääb-Sanyal V.

Breast Care (Basel). 2016 Jun;11(3):183-7. doi: 10.1159/000446359. Epub 2016 Jun 23.

PMID:
27493618
2.

Evaluation issues in the Swedish Two-County Trial of breast cancer screening: An historical review.

Tabar L, Chen TH, Hsu CY, Wu WY, Yen AM, Chen SL, Chiu SY, Fann JC, Beckmann K, Smith RA, Duffy SW.

J Med Screen. 2017 Mar;24(1):27-33. doi: 10.1177/0969141316631375. Epub 2016 Jun 23.

3.

Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.

Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ, Wolf AM, DeSantis C, Lortet-Tieulent J, Andrews K, Manassaram-Baptiste D, Saslow D, Smith RA, Brawley OW, Wender R; American Cancer Society..

JAMA. 2015 Oct 20;314(15):1599-614. doi: 10.1001/jama.2015.12783. Erratum in: JAMA. 2016 Apr 5;315(13):1406.

4.

Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study.

Suhrke P, Zahl PH.

Cancer Med. 2015 Aug;4(8):1303-8. doi: 10.1002/cam4.474. Epub 2015 May 20.

5.

Bias in Observational Studies of the Association between Menopausal Hormone Therapy and Breast Cancer.

Zahl PH, Mæhlen J.

PLoS One. 2015 May 4;10(5):e0124076. doi: 10.1371/journal.pone.0124076. eCollection 2015 May 4.

6.

Overdiagnosis: epidemiologic concepts and estimation.

Bae JM.

Epidemiol Health. 2015 Feb 10;37:e2015004. doi: 10.4178/epih/e2015004. eCollection 2015 Feb 10.

7.

Mammography screening in three Finnish residential areas: comprehensive population-based study of breast cancer incidence and incidence-based mortality 1976-2009.

Parvinen I, Heinävaara S, Anttila A, Helenius H, Klemi P, Pylkkänen L.

Br J Cancer. 2015 Mar 3;112(5):918-24. doi: 10.1038/bjc.2014.642. Epub 2015 Feb 17.

8.

Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods.

Carter JL, Coletti RJ, Harris RP.

BMJ. 2015 Jan 7;350:g7773. doi: 10.1136/bmj.g7773. Review.

9.

Higher incidence of premenopausal breast cancer in less developed countries; myth or truth?

Ghiasvand R, Adami HO, Harirchi I, Akrami R, Zendehdel K.

BMC Cancer. 2014 May 19;14:343. doi: 10.1186/1471-2407-14-343.

10.

Lead-time models should not be used to estimate overdiagnosis in cancer screening.

Zahl PH, Jørgensen KJ, Gøtzsche PC.

J Gen Intern Med. 2014 Sep;29(9):1283-6. doi: 10.1007/s11606-014-2812-2. Epub 2014 Mar 4. Review.

11.

Were our estimates of overdiagnosis with mammography screening in the United States "based on faulty science"?

Bleyer A.

Oncologist. 2014 Feb;19(2):113-26. doi: 10.1634/theoncologist.2013-0383. No abstract available.

12.

Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort study.

Lund E, Mode N, Waaseth M, Thalabard JC.

BMC Cancer. 2013 Dec 30;13:614. doi: 10.1186/1471-2407-13-614.

13.

Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis.

Zahl PH, Jørgensen KJ, Gøtzsche PC.

Br J Cancer. 2013 Oct 1;109(7):2014-9. doi: 10.1038/bjc.2013.427. Epub 2013 Aug 20.

14.

The benefits and harms of breast cancer screening: an independent review.

Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M.

Br J Cancer. 2013 Jun 11;108(11):2205-40. doi: 10.1038/bjc.2013.177. Epub 2013 Jun 6. Review. No abstract available.

15.

Overdiagnosis among women attending a population-based mammography screening program.

Falk RS, Hofvind S, Skaane P, Haldorsen T.

Int J Cancer. 2013 Aug 1;133(3):705-12. doi: 10.1002/ijc.28052. Epub 2013 Feb 25.

16.

Women's views on overdiagnosis in breast cancer screening: a qualitative study.

Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, Dhillon H, McCaffery K.

BMJ. 2013 Jan 23;346:f158. doi: 10.1136/bmj.f158.

17.

Most breast cancer screening trials have a flawed design.

Gurnani N, Srivastava A.

Indian J Surg. 2011 Dec;73(6):419-22. doi: 10.1007/s12262-011-0342-2. Epub 2011 Oct 25.

18.

The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS.

Wallis MG, Clements K, Kearins O, Ball G, Macartney J, Lawrence GM.

Br J Cancer. 2012 May 8;106(10):1611-7. doi: 10.1038/bjc.2012.151. Epub 2012 Apr 19.

19.

Long-term prognosis of breast cancer detected by mammography screening or other methods.

Lehtimäki T, Lundin M, Linder N, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H, Lundin J.

Breast Cancer Res. 2011;13(6):R134. doi: 10.1186/bcr3080. Epub 2011 Dec 28.

20.

Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data.

Seigneurin A, François O, Labarère J, Oudeville P, Monlong J, Colonna M.

BMJ. 2011 Nov 23;343:d7017. doi: 10.1136/bmj.d7017.

Supplemental Content

Support Center